Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease

Data de publicação:

Autores da FMUP

  • Francisco Jorge Nunes De Melo

    Autor

  • Manuel Guilherme Gonçalves Macedo

    Autor

  • Claudia Camila Rodrigues Pereira Dias

    Autor

  • Maria De Fátima Machado Henriques Carneiro

    Autor

  • Fernando José Magro Dias

    Autor

Participantes de fora da FMUP

  • Pinto Lopes, P
  • Afonso, J
  • Pinto Lopes, R
  • Rocha, C
  • Melo, D

Unidades de investigação

Abstract

INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) is a membrane-bound glycoprotein that acts as a receptor but also exists in a soluble form. It has been recognized as a mediator of inflammation and considered a biomarker in inflammatory bowel disease (IBD). METHODS: We evaluated a prospectively recruited cohort, consisting of 101 patients with IBD, using validated clinical indexes; 22 patients with ulcerative colitis (UC) underwent endoscopic evaluation. Fecal DPP-4 (fDPP-4) levels were analyzed and correlated with clinical scores, Mayo endoscopic score (in UC patients), serum DPP-4, C-reactive protein, and fecal calprotectin. Immunohistochemical staining for DPP-4 in intestinal biopsies was also performed. RESULTS: When compared with remitters, median fDPP-4 levels were higher in patients with ileal Crohn's disease (CD) (7,584 [1,464-7,816] vs 2,104 [630-2,676] ng/mL, P = 0.015) and lower in patients with UC exhibiting clinical activity (1,213 [559-1,682] vs 7,814 [2,555-7,985] ng/mL, P < 0.001). Patients with UC presenting endoscopic activity also had lower levels than remitters (939 [559-1,420] vs 7,544 [4,531-7,940] ng/mL, P = 0.006). Fecal DPP-4 discriminated clinical activity from remission with areas under the curve of 0.76 (95% confidence interval [CI] 0.58-0.94, P = 0.015) and 0.80 (95% CI 0.68-0.93, P < 0.001) in CD and UC, respectively; it allowed to differentiate endoscopic activity in patients with UC, with areas under the curve of 0.84 (95% CI 0.63-1.00, P = 0.009). Immunohistochemical analysis revealed higher DPP-4 apical expression in UC remitters, but no statistically significant differences were revealed between patients with ileal CD. DISCUSSION: Our results suggest that fDPP-4 can be used as a biomarker of IBD activity, particularly in UC. The expression profiles in intestinal tissue might represent a functional compartmentalization of DPP-4 expression.

Dados da publicação

ISSN/ISSNe:
2155-384X, 2155-384X

Clinical and Translational Gastroenterology  Nature Publishing Group

Tipo:
Article
Páginas:
320-
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 6

Citações Recebidas na Scopus: 9

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • CD26/DIPEPTIDYLPEPTIDASE IV; EXPRESSION; CD26; TRUNCATION; RANTES; DPP4

Financiamento

Proyectos asociados

Gut microbiome and IBD therapy: an interplay?

Investigador Principal: Fernando José Magro Dias

Estudo Observacional Académico (GutIBD) . 2021

Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.

Investigador Principal: Fernando José Magro Dias

Estudo Observacional Académico (IronIBD) . 2021

Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.

Investigador Principal: Fernando José Magro Dias

Estudo Observacional Académico (4WARD) . 2021

Gastric Cancer Morphological, Immunophenotypic and molecular heterogeneity

Investigador Principal: Maria de Fátima Machado Henriques Carneiro

Estudo Clínico Académico . 2020

Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2019

Citar a publicação

Partilhar a publicação